Advertisement
Canada markets open in 2 hours 40 minutes

  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CAD/USD

    0.7306
    -0.0014 (-0.19%)
     

  • CRUDE OIL

    82.91
    -0.45 (-0.54%)
     

  • Bitcoin CAD

    90,763.33
    +21.62 (+0.02%)
     

  • CMC Crypto 200

    1,433.77
    +9.67 (+0.68%)
     

  • GOLD FUTURES

    2,328.80
    -13.30 (-0.57%)
     

  • RUSSELL 2000

    2,002.64
    +35.17 (+1.79%)
     

  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     

  • NASDAQ futures

    17,699.00
    +92.25 (+0.52%)
     

  • VOLATILITY

    15.81
    +0.12 (+0.76%)
     

  • FTSE

    8,083.08
    +38.27 (+0.48%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • CAD/EUR

    0.6835
    -0.0001 (-0.01%)
     

Editas Medicine to Host Conference Call Discussing Third Quarter 2021 Results and Corporate Update

Editas Medicine, Inc.
·1 min read

CAMBRIDGE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday, November 8, 2021, at 8:00 a.m. ET to provide a corporate update and results for the third quarter of 2021.

To access the conference call:

  • U.S. callers should dial 877-407-0989 and international callers should dial 201-389-0921 approximately five minutes before the call begins.

  • Participants should ask to be connected to the Editas Medicine earnings conference call.

A live webcast and replay of the conference call can also be accessed in the Investors section of the Editas Medicine website at https://www.editasmedicine.com/.

ADVERTISEMENT

About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Contacts:
Media
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com

Investors
Ron Moldaver
(617) 401-9052
ir@editasmed.com